Aliskiren/amlodipine

Drug Profile

Aliskiren/amlodipine

Alternative Names: Amlodipine/aliskiren; Rasilamlo; Rasilez Amlo; SPA 100; Tekamlo

Latest Information Update: 05 Jun 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Amides; Antihypertensives; Dihydropyridines; Fumarates; Small molecules
  • Mechanism of Action Calcium channel antagonists; Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 11 Mar 2015 Launched for Hypertension in Argentina, Brazil, Austria, Ireland, Portugal, Poland, Switzerland and India (PO) before March 2015
  • 28 Mar 2014 Launched prior to March 2014 for Hypertension in Czech Republic, Italy and Netherlands (PO)
  • 24 Mar 2014 Registered for Hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top